| Year |
Citation |
Score |
| 2021 |
Shukla S, Ying W, Gray F, Yao Y, Simes ML, Zhao Q, Miao H, Cho HJ, González-Alonso P, Winkler A, Lund G, Purohit T, Kim E, Zhang X, Ray JM, ... He S, et al. Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nature Chemical Biology. PMID 34155404 DOI: 10.1038/s41589-021-00815-5 |
0.324 |
|
| 2020 |
Kregel S, Bagamasbad P, He S, LaPensee E, Raji Y, Brogley M, Chinnaiyan A, Cieslik M, Robins DM. Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element. Nucleic Acids Research. PMID 32198885 DOI: 10.1093/Nar/Gkaa178 |
0.32 |
|
| 2016 |
Gray F, Cho HJ, Shukla S, He S, Harris A, Boytsov B, Jaremko Ł, Jaremko M, Demeler B, Lawlor ER, Grembecka J, Cierpicki T. BMI1 regulates PRC1 architecture and activity through homo- and hetero-oligomerization. Nature Communications. 7: 13343. PMID 27827373 DOI: 10.1038/Ncomms13343 |
0.447 |
|
| 2015 |
He S, Malik B, Borkin D, Miao H, Shukla S, Kempinska K, Purohit T, Wang J, Chen L, Parkin B, Malek SN, Danet-Desnoyers G, Muntean AG, Cierpicki T, Grembecka J. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia. PMID 26084867 DOI: 10.1038/Leu.2015.144 |
0.365 |
|
| 2015 |
Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 27: 589-602. PMID 25817203 DOI: 10.1016/J.Ccell.2015.02.016 |
0.428 |
|
| 2015 |
Shukla S, Zhao Q, Ying W, Gray F, Vandenberg K, Lund G, Boytsov B, He S, Grembecka J, Cierpicki T. Abstract 3520: Small molecule inhibitors of ring1B-Bmi1 E3 ligase target polycomb repressive complex 1 activity and regulate cell proliferation Cancer Research. 75: 3520-3520. DOI: 10.1158/1538-7445.Am2015-3520 |
0.383 |
|
| 2014 |
Murai MJ, Pollock J, He S, Miao H, Purohit T, Yokom A, Hess JL, Muntean AG, Grembecka J, Cierpicki T. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. Blood. 124: 3730-7. PMID 25305204 DOI: 10.1182/Blood-2014-01-550079 |
0.419 |
|
| 2014 |
He S, Senter TJ, Pollock J, Han C, Upadhyay SK, Purohit T, Gogliotti RD, Lindsley CW, Cierpicki T, Stauffer SR, Grembecka J. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. Journal of Medicinal Chemistry. 57: 1543-56. PMID 24472025 DOI: 10.1021/Jm401868D |
0.396 |
|
| 2014 |
Cierpicki T, Murai MJ, Pollock J, Purohit T, He S, Yokom A, Hess JL, Muntean AG, Grembecka J. Abstract 3225: LEDGF IBD domain represents therapeutic target for MLL leukemia and HIV Cancer Research. 74: 3225-3225. DOI: 10.1158/1538-7445.Am2014-3225 |
0.476 |
|
| 2014 |
Grembecka JE, He S, Senter TJ, Borkin D, Pollock J, Han C, Upadhyay SK, Purohit T, Miao H, Gogliotti RDGD, Lindsley CW, Cierpicki T, Stauffer SR. Abstract 2534: High-affinity small molecule inhibitors of the menin-MLL interaction reverse oncogenic transformation mediated by MLL fusion proteins in leukemia Cancer Research. 74: 2534-2534. DOI: 10.1158/1538-7445.Am2014-2534 |
0.437 |
|
| 2012 |
Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T, Reddy G, Chruszcz M, Grembecka J, Cierpicki T. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood. 120: 4461-9. PMID 22936661 DOI: 10.1182/Blood-2012-05-429274 |
0.464 |
|
| 2012 |
Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, Hess JL, Cierpicki T. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology. 8: 277-84. PMID 22286128 DOI: 10.1038/Nchembio.773 |
0.459 |
|
| 2011 |
Cierpicki T, He S, Purohit T, Murai M, Hartley T, Grembecka J. Targeting LEDGF Interactions in MLL Leukemia Blood. 118: 2500-2500. DOI: 10.1182/Blood.V118.21.2500.2500 |
0.458 |
|
| 2011 |
Grembecka J, He S, Shi A, Purohit T, Muntean AG, Li X, Hartley T, Sun D, Hess JL, Cierpicki T. Targeting Menin-MLL Interaction to Inhibit MLL Fusion Oncoproteins in Leukemia Blood. 118: 2497-2497. DOI: 10.1182/Blood.V118.21.2497.2497 |
0.442 |
|
| 2010 |
He S, Ni S, Hegde S, Wang X, Sharda DR, August A, Paulson RF, Hankey PA. Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk. Journal of Virology. 84: 2223-35. PMID 20016000 DOI: 10.1128/Jvi.02090-09 |
0.399 |
|
| 2009 |
Hegde S, Ni S, He S, Yoon D, Feng GS, Watowich SS, Paulson RF, Hankey PA. Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene. 28: 3349-59. PMID 19581930 DOI: 10.1038/Onc.2009.202 |
0.632 |
|
| 2006 |
He S, Ni S, Paulson RF, Correll PH. gp55 from Friend Erythroleukemia Virus Induces Oligomerization and Cell Surface Localization of a Truncated Form of the STK Receptor Tyrosine Kinase. Blood. 108: 1146-1146. DOI: 10.1182/Blood.V108.11.1146.1146 |
0.623 |
|
| Show low-probability matches. |